Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression of cancer.
The drug candidate is currently being reviewed by the US Food and Drug Administration (FDA), the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare, and other regulatory agencies across the globe as a potential treatment for advanced RCC.
As per the deal, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities.
SFJ will be entitled to receive milestone payments under the agreement.
Furthermore, following approval, Pfizer plans to commercialize axitinib for this indication and SFJ will receive earn-out payments under the agreement.